FindTrial
Sign In

Standard DAPT duration

DRUG2 trials

Sponsors

Federico II University, Vincent ROULE

Conditions

Acute Coronary SyndromeAntiplatelet TherapyChronic Coronary SyndromeCoronary Artery DiseaseCoronary Artery Disease (CAD)Elderly (People Aged 65 or More)Myocardial InfarctionPercutaneous Coronary Intervention (PCI)

Phase 3

Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI
Not yet recruitingNCT07164859
Vincent ROULEAntiplatelet Therapy, Coronary Artery Disease (CAD), Elderly (People Aged 65 or More) +1
Start: 2025-10-31End: 2029-10-31Target: 1700Updated: 2025-10-01

Phase 4

Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES
Active, not recruitingNCT04135989
Federico II UniversityAcute Coronary Syndrome, Chronic Coronary Syndrome, Coronary Artery Disease +1
Start: 2020-01-01End: 2024-10-24Target: 2106Updated: 2024-02-23

Related Papers

Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: The PARTHENOPE Randomized Trial.
2025-08-302 citations
Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trial.
2025-01-016 citations
Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI.
2023-08-102 citations